Coloplast announced today that it has completed the acquisition of Nine Continents Medical, Inc., an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The acquisition price consists of USD 145 million upfront cash payment and an additional contingent future milestone payment. Founded in 2014, Nine Continents Medical, Inc. is a privately held company that has developed an innovative solution for over-active bladder (OAB), a condition characterized by a range of symptoms including the need to urinate more frequently, increased urgency, incontinence or leakage, and a need to urinate at night.
Read the full article: Coloplast Acquires Nine Continents Medical, Inc. //
Source: https://www.globenewswire.com/news-release/2020/11/03/2119135/0/en/Coloplast-acquires-Nine-Continents-Medical-Inc.html